SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Barbara H McGovern, Christopher B Ford, Matthew R Henn, …, Roger J Pomerantz, John G Auninš, Michele Trucksis

• DOI: 10.1093/cid/ciaa387
• PMID: 32255488
• PMCID: PMC8204772